Table 1.
Variable | Statin (N= 246) | No Statin (N= 134) | P value |
---|---|---|---|
Age, years | 69.0 ± 13.3 | 68.0 ± 13.9 | 0.4 |
Male (%) | 145 (59) | 68 (51) | 0.1 |
Race/Ethnicity (%) | 0.7 | ||
Caucasian | 179 (73) | 98 (73) | |
Hispanic | 29 (12) | 20 (15) | |
African American | 31 (13) | 13 (10) | |
Asian | 7 (3) | 3 (2) | |
BMI, kg/m2 | 27.4 ± 6.2 | 26.6 ± 6.5 | 0.2 |
Tobacco, former or current (%) | 168 (69) | 87 (66) | 0.5 |
CHF (%) | 79 (33) | 36 (27) | 0.3 |
DM (%) | 167 (68) | 65 (50) | <0.001 |
GFR, ml/min | 59.8 ± 39.4 | 61.2 ± 40.8 | 0.8 |
HTN (%) | 221 (90) | 103 (77) | <0.001 |
SBP (mmHg) | 134 ± 23 | 132 ± 23 | 0.99 |
CAD (%) | 144 (59) | 40 (31) | <0.001 |
History of MI (%) | 72 (29) | 12 (9) | <0.001 |
Ejection Fraction | 53.1 ± 17.3 | 52.6 ± 18.5 | 0.9 |
History of Stroke/ TIA (%) | 58 (24) | 17 (13) | 0.01 |
History of Malignancy (%) | 30 (12) | 14 (10) | 0.6 |
COPD (%) | 40 (16) | 16 (12) | 0.2 |
History of AAA (%) | 10 (4) | 4 (3) | 0.6 |
History of Carotid Stenosis (%) | 42 (18) | 5 (4) | <0.001 |
History of Contralateral Amputation (%) | 14 (10) | 37 (15) | 0.2 |
Total Cholesterol, mg/dl | 142 ± 41 | 167 ± 60 | 0.001 |
LDL, mg/dl | 75 ± 28 | 96 ± 40 | <0.001 |
HDL, mg/dl | 39 ± 18 | 35 ± 17 | 0.3 |
TG, mg/dl | 130 ± 65 | 145 ± 84 | 0.2 |
HbA1c, % | 7.9 ± 2.2 | 7.8 ± 2.1 | 0.9 |
ACE inhibitor or ARB (%) | 162 (66) | 57 (43) | <0.001 |
Beta blocker (%) | 154 (63) | 47 (35) | <0.001 |
Aspirin (%) | 225 (91) | 117 (87) | 0.2 |
Clopidogrel (%) | 168 (68) | 77 (57) | 0.04 |
Other Lipid Medication* | 31 (13) | 12 (9) | 0.6 |
Rutherford score | 0.8 | ||
4 | 38 (15) | 22 (16) | |
5 | 177 (73) | 95 (70) | |
6 | 29 (12) | 18 (13) | |
ABI† | 0.48 ± 0.24 | 0.48 ± 0.27 | 0.9 |
TBI | 0.19 ± 0.17 | 0.18 ± 0.20 | 0.7 |
Abbreviations: AAA, abdominal aortic aneurysm; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; GFR, glomerular filtration rate; HBA1c, hemoglobin A1c; HDL, high density lipoprotein; HTN, hypertension; LDL, low density lipoprotein; TG, triglyceride; TIA, transient ischemic attack; TBI, toe brachial index
Other lipid medications included fibrate, fish oil, niacin, and ezetimibe.
Excluding subjects with ABI>1.4, for whom TBI was also measured